Key U.S. Scientist Pushes to Hang Onto Last Remaining Smallpox Virus

A health worker vaccinates a child against smallpox, circa 1962, in what is now the Democratic Republic of the Congo. A U.S. scientist is advising against destroying the world's final known stocks of smallpox, which was eradicated from nature in the 1970s.
National Journal
Diane Barnes
May 2, 2014, 4:01 a.m.

A U.S. sci­ent­ist has ad­vised against elim­in­at­ing the world’s last known stocks of small­pox, just weeks be­fore na­tions are set to re­con­sider de­struc­tion.

“The re­search agenda with live [small­pox] vir­us is not yet fin­ished,” In­ger Da­mon, who over­sees stud­ies of the agent at the Cen­ters for Dis­ease Con­trol and Pre­ven­tion in At­lanta, said in a newly pub­lished art­icle co-au­thored with two oth­er sci­ent­ists.

Da­mon, who heads the agency’s Poxvir­us and Ra­bies Branch, and her col­leagues ar­gue that re­lated agents can­not al­ways sub­sti­tute for live small­pox vir­us in lab ex­per­i­ments to quickly de­tect and con­tain the his­tor­ic­al scourge, should it re-emerge.

A glob­al erad­ic­a­tion cam­paign wiped out small­pox from nature in the 1970s. However, the United States and oth­er coun­tries have spent dec­ades de­vel­op­ing new vac­cines and drugs in case the agent is re­leased from a secret stock­pile, or as­sembled from scratch us­ing emer­ging tech­no­lo­gies.

In an in­ter­view with Glob­al Se­cur­ity News­wire, Da­mon ad­vised that state par­ti­cipants in the World Health As­sembly — the top de­lib­er­at­ive body of the World Health Or­gan­iz­a­tion — again delay set­ting any dead­line for des­troy­ing the fi­nal known sup­plies of small­pox vir­us. The re­main­ing caches are held at CDC headquar­ters and at a state labor­at­ory in Rus­sia.

“We can’t pre­dict what the res­ults of the next “¦ ex­per­i­ments are go­ing to be,” she said by tele­phone on Wed­nes­day. “If we could do that, we could give a dis­tinct and a defin­it­ive [de­struc­tion] timeline.”

Her art­icle — writ­ten jointly with Clarissa Dam­aso of Brazil’s Fed­er­al Uni­versity of Rio de Janeiro and Grant Mc­Fad­den of the Uni­versity of Flor­ida — makes the case that fur­ther re­search with live vir­us is “vi­tal” to de­vel­op­ing safer vac­cines, fully li­censed drugs, and faster de­tec­tion strategies.

Speak­ing to GSN, Da­mon said the art­icle does not in­dic­ate what po­s­i­tion the Obama ad­min­is­tra­tion will take at the World Health As­sembly’s May 19-24 meet­ing.

She ex­pressed hope, though, that her piece “will be im­port­ant in in­form­ing the of­fi­cial U.S. stance.”

Rus­sia and the United States suc­cess­fully pushed in 2011 to delay any con­sid­er­a­tion of a de­struc­tion dead­line un­til this year. That ex­ten­ded a series of post­pone­ments ever since a WHO ad­vis­ory com­mit­tee in 1990 re­com­men­ded des­troy­ing the re­main­ing vir­us.

Ad­visers to the glob­al health agency reached gen­er­al agree­ment in Septem­ber that live vir­us stocks “need no longer be re­tained for fur­ther es­sen­tial re­search.” Its con­clu­sions were echoed two months later by an in­de­pend­ent pan­el of ex­perts con­vened to ex­am­ine re­cent de­vel­op­ments in small­pox stud­ies.

Speak­ing to GSN on Tues­day, epi­demi­olo­gist Don­ald Hende­r­son ar­gued in fa­vor of des­troy­ing the re­main­ing vir­us stocks. He re­com­men­ded fo­cus­ing on en­sur­ing ad­equate in­ter­na­tion­al sup­plies of older, less ex­pens­ive vac­cine in­stead of pur­su­ing fur­ther re­search with live vir­us.

“We’ve had a couple of stabs at try­ing to de­vel­op these products as called for by the [United States] way back when, and it hasn’t worked,” said Hende­r­son, who headed the World Health Or­gan­iz­a­tion’s glob­al small­pox erad­ic­a­tion pro­gram in the 1960s and 1970s.

“If it comes to a ma­jor­ity vote in the World Health As­sembly, which it’s al­most come to sev­er­al times, I think the over­whelm­ing de­sire will be to des­troy,” Hende­r­son said.

Hende­r­son and Isao Ar­ita, an­oth­er former lead­er of the WHO small­pox erad­ic­a­tion ef­fort, wrote in an April journ­al art­icle that “lo­gic dic­tates an early date” for the agent’s de­struc­tion.

Re­tain­ing the stock­piles in­def­in­itely, Hende­r­son told GSN, could con­trib­ute to in­ter­na­tion­al sus­pi­cion that Wash­ing­ton and Mo­scow want the vir­us as a “de­terrent” that they may choose to weapon­ize.

The vir­us ori­gin­ated early in hu­man his­tory, and is be­lieved to have killed 300 mil­lion people between 1900 and its elim­in­a­tion from the en­vir­on­ment.

What We're Following See More »
SEVEN-POINT LEAD IN A FOUR-WAY
Quinnipiac Has Clinton Over 50%
14 minutes ago
THE LATEST

Hillary Clinton leads Donald Trump 51%-41% in a new Quinnipiac poll released today. Her lead shrinks to seven points when the third-party candidates are included. In that scenario, she leads 45%-38%, with Gary Johnson pulling 10% and Jill Stein at 4%.

Source:
PROCEDURES NOT FOLLOWED
Trump Not on Ballot in Minnesota
2 hours ago
THE LATEST
MIGHT STILL ACCEPT FOREIGN AND CORPORATE MONEY
Chelsea to Stay on Board of Clinton Foundation
2 hours ago
THE LATEST

Is the Clinton family backtracking on some of its promises to insulate the White House from the Clinton Foundation? Opposition researchers will certainly try to portray it that way. A foundation spokesman said yesterday that Chelsea Clinton will stay on its board, and that the "foundation’s largest project, the Clinton Health Access Initiative, might continue to accept foreign government and corporate funding."

Source:
INTERCEPT IN MIDDLE EAST
Navy Calls Iranian Ships’ Actions Dangerous, Unprofessional
3 hours ago
THE LATEST

"Four Iranian ships made reckless maneuvers close to a U.S. warship this week, the Pentagon said Thursday, in an incident that officials said could have led to dangerous escalation." The four Iranian vessels engaged in a "high-speed intercept" of a U.S. destroyer in the Strait of Hormuz. A Navy spokesman said the Iranina actions "created a dangerous, harassing situation that could have led to further escalation including additional defensive measures" by the destroyer.

Source:
$300 SAVINGS CARD
Under Pressure, EpiPen Maker Drops Prices
3 hours ago
THE LATEST

Amid public outcry and the threat of investigation by the Senate Judiciary Committee, Mylan has agreed to effectively drop the price of EpiPens. "The company, which did not lower the drug's list price, said it would reduce the patient cost of EpiPen through the use of a savings card, which will cover up to $300 of EpiPen 2-Pak."

Source:
×